Endocrine Abstracts

Background: Immune checkpoint inhibitors (ICPIs) are indicated as treatment for metastatic renal cell carcinoma (RCC) and melanoma, among other malignancies. This group of agents is associated with immune-related adverse events (irAEs). We aimed to further investigate the association of immune-related thyroid disorders (irTDs) with clinical outcomes and mortality rates in patients with RCC or melanoma who were treated with ICPIs.Methods: We retrospective...

Introduction: Severe insulinopenic diabetes (SID) is a rare complication of treatment with immune checkpoint inhibitors (ICPI). We describe herein the clinical characteristics, natural history and potential predictors of SID in cancer patients treated with ICPI.Methods: We identified and retrospectively retrieved pertinent clinical data of all patients who presented with new onset SID following treatment with ICPI between 2015 and 2022 at the Tel Aviv-So...